Sucampo Pharma (SCMP) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- US stock futures gain as oil pulls back ahead of Fed decision
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Guggenheim Reiterates Buy on Sucampo Pharma (SCMP) Following 1Q Earnings
May 4, 2016 1:07 PM EDTGuggenheim reiterated a Buy rating and $29.00 price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) following the company's 1Q earnings report. SCMP reported 1Q16 diluted EPS of $0.21, in line with consensus. Management reiterated its '16 adjusted EPS guidance of $1.02 at the midpoint (consensus was $1.05).
Analyst... More



